Bristol Capital Surpluse from 2010 to 2024

BMY Stock  USD 58.78  0.09  0.15%   
Bristol Myers Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse is likely to outpace its year average in 2024. During the period from 2010 to 2024, Bristol Myers Capital Surpluse regression line of annual values had r-squared of  0.74 and arithmetic mean of  20,280,299,167. View All Fundamentals
 
Capital Surpluse  
First Reported
2009-06-30
Previous Quarter
45.3 B
Current Value
44.8 B
Quarterly Volatility
19 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol Myers' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.3 B, Interest Expense of 1.2 B or Selling General Administrative of 3.6 B, as well as many indicators such as Price To Sales Ratio of 2.98, Dividend Yield of 0.0374 or PTB Ratio of 6.92. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.
  
Check out the analysis of Bristol Myers Correlation against competitors.

Latest Bristol Myers' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Bristol Myers Squibb over the last few years. It is Bristol Myers' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Bristol Capital Surpluse Regression Statistics

Arithmetic Mean20,280,299,167
Geometric Mean7,356,782,079
Coefficient Of Variation113.64
Mean Deviation21,647,292,333
Median3,114,000,000
Standard Deviation23,046,146,354
Sample Variance531124861.8T
Range53.1B
R-Value0.86
Mean Square Error146999676.6T
R-Squared0.74
Significance0.000036
Slope4,441,988,080
Total Sum of Squares7435748064.9T

Bristol Capital Surpluse History

202454.5 B
202351.9 B
202245.2 B
202144.4 B
202044.3 B
201943.7 B
20182.1 B

About Bristol Myers Financial Statements

Bristol Myers investors use historical fundamental indicators, such as Bristol Myers' Capital Surpluse, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse51.9 B54.5 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.